Acanthosis nigricanshttps://en.wikipedia.org/wiki/Acanthosis_nigricans
☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye. Li komen nan moun ki obèz.
Pigmantasyon nwa ak ondilasyon nan tou de bra yo sijere Acanthosis nigricans.
relevance score : -100.0%
References Acanthosis Nigricans 28613711 NIH
Acanthosis nigricans se yon manifestasyon po yon maladi ki kache. Li souvan parèt nan pli po tankou kou a, armpits, ak arèt, sanble tankou plak velours nwa ak bor klè. Kondisyon sa a anjeneral lye ak dyabèt ak rezistans ensilin, men nan ka ki ra, li ka montre kansè andedan kò a. Li ta ka parèt tou akòz pwoblèm òmòn oswa nan pran medikaman espesifik tankou estewoyid ak grenn planin.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Current treatment options for acanthosis nigricans 30122971 NIH
Acanthosis nigricans (AN) se yon maladi po komen ki lye ak divès pwoblèm sante tankou rezistans ensilin, dyabèt, obezite, sèten kansè, pwoblèm ormon, ak reyaksyon a medikaman. Trete AN konsantre sou adrese pwoblèm sante ki kache yo. Okòmansman, doktè tcheke pou siy sendwòm rezistans ensilin, ki gen ladan obezite, kolestewòl wo, tansyon wo, ak dyabèt tip 2. Doktè yo souvan preskri topical retinoids kòm premye chwa tretman, ki ka ede ak epesman po. Sepandan, yo ka pa totalman adrese po a nwa. Lòt opsyon tretman (salicylic acid, podophyllin, urea, calcipotriol) bezwen aplikasyon souvan.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Kòz
Li anjeneral rive nan moun ki poko gen laj 40 an, li ka eritye jenetikman epi li asosye ak obezite oswa andokrinopati, tankou ipothyroidism, akromegali, maladi ovè polisistik, dyabèt ki reziste ensilin oswa maladi Cushing.
○ Tretman - Medikaman OTC
#40% urea cream